Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. (Q54484711)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22967996

Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22967996

0 references

metastatic breast cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

A Awada

1

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22967996

L Dirix

2

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22967996

L Manso Sanchez

3

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22967996

B Xu

4

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22967996

T Luu

5

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22967996

V Diéras

6

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22967996

D L Hershman

7

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22967996

V Agrapart

8

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22967996

R Ananthakrishnan

9

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22967996

E Staroslawska

10

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22967996

publication date

11 September 2012

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22967996

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22967996

24

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22967996

1

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22967996

109-116

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22967996

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS284

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS284

21 January 2018

A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS284

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS284

21 January 2018

Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS284

21 January 2018

Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS284

21 January 2018

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS284

21 January 2018

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS284

21 January 2018

Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS284

21 January 2018

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS284

21 January 2018

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS284

21 January 2018

Antitumor activity of HER-2 inhibitors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS284

21 January 2018

Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS284

21 January 2018

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS284

21 January 2018

A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS284

21 January 2018

The cardiac safety of trastuzumab in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS284

21 January 2018

A single-dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS284

21 January 2018

Vinorelbine in the management of breast cancer: New perspectives, revived role in the era of targeted therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS284

21 January 2018

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS284

21 January 2018

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS284

21 January 2018

A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS284

21 January 2018

Phase II Study of Vinorelbine Plus Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS284

21 January 2018

A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS284

21 January 2018

Combination of Trastuzumab and Vinorelbine in Metastatic Breast Cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS284

21 January 2018

Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS284

21 January 2018

A phase II trial of docetaxel and vinorelbine in patients with advanced breast cancer previously treated with anthracyclines

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS284

21 January 2018

Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS284

21 January 2018

A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS284

21 January 2018

Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS284

21 January 2018

Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS284

21 January 2018

Identifiers

10.1093/ANNONC/MDS284

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22967996

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22967996

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54484711&oldid=1672304097"